These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

574 related items for PubMed ID: 15183903

  • 1. Epstein-Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative disease.
    Burns DM, Crawford DH.
    Blood Rev; 2004 Sep; 18(3):193-209. PubMed ID: 15183903
    [Abstract] [Full Text] [Related]

  • 2. Epstein-Barr virus, B cell lymphoproliferative disease, and SCID mice: modeling T cell immunotherapy in vivo.
    Johannessen I, Bieleski L, Urquhart G, Watson SL, Wingate P, Haque T, Crawford DH.
    J Med Virol; 2011 Sep; 83(9):1585-96. PubMed ID: 21739450
    [Abstract] [Full Text] [Related]

  • 3. Determining virological, serological and immunological parameters of EBV infection in the development of PTLD.
    Davis JE, Sherritt MA, Bharadwaj M, Morrison LE, Elliott SL, Kear LM, Maddicks-Law J, Kotsimbos T, Gill D, Malouf M, Falk MC, Khanna R, Moss DJ.
    Int Immunol; 2004 Jul; 16(7):983-9. PubMed ID: 15159377
    [Abstract] [Full Text] [Related]

  • 4. Review of Epstein-Barr virus and post-transplant lymphoproliferative disorder post-solid organ transplantation.
    Lim WH, Russ GR, Coates PT.
    Nephrology (Carlton); 2006 Aug; 11(4):355-66. PubMed ID: 16889577
    [Abstract] [Full Text] [Related]

  • 5. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation.
    Taylor AL, Marcus R, Bradley JA.
    Crit Rev Oncol Hematol; 2005 Oct; 56(1):155-67. PubMed ID: 15979320
    [Abstract] [Full Text] [Related]

  • 6. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases.
    Styczynski J, Einsele H, Gil L, Ljungman P.
    Transpl Infect Dis; 2009 Oct; 11(5):383-92. PubMed ID: 19558376
    [Abstract] [Full Text] [Related]

  • 7. Epstein-Barr virus-associated lymphoproliferative disease after allogeneic haematopoietic stem cell transplantation: molecular monitoring and early treatment of high-risk patients.
    Meijer E, Cornelissen JJ.
    Curr Opin Hematol; 2008 Nov; 15(6):576-85. PubMed ID: 18832928
    [Abstract] [Full Text] [Related]

  • 8. Reconstitution of the latent T-lymphocyte response to Epstein-Barr virus is coincident with long-term recovery from posttransplant lymphoma after adoptive immunotherapy.
    Sherritt MA, Bharadwaj M, Burrows JM, Morrison LE, Elliott SL, Davis JE, Kear LM, Slaughter RE, Bell SC, Galbraith AJ, Khanna R, Moss DJ.
    Transplantation; 2003 May 15; 75(9):1556-60. PubMed ID: 12792514
    [Abstract] [Full Text] [Related]

  • 9. Treatment options for post-transplant lymphoproliferative disorder and other Epstein-Barr virus-associated malignancies.
    Davis JE, Moss DJ.
    Tissue Antigens; 2004 Apr 15; 63(4):285-92. PubMed ID: 15009802
    [Abstract] [Full Text] [Related]

  • 10. Adoptive immunotherapy for Epstein-Barr virus-associated lymphoproliferative disorders complicating marrow allografts.
    O'Reilly RJ, Small TN, Papadopoulos E, Lucas K, Lacerda J, Koulova L.
    Springer Semin Immunopathol; 1998 Apr 15; 20(3-4):455-91. PubMed ID: 9870257
    [No Abstract] [Full Text] [Related]

  • 11. Adoptive immunotherapy with allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes for recurrent, EBV-positive Hodgkin disease.
    Lucas KG, Salzman D, Garcia A, Sun Q.
    Cancer; 2004 May 01; 100(9):1892-901. PubMed ID: 15112270
    [Abstract] [Full Text] [Related]

  • 12. Adoptive cell therapy with donor lymphocytes for EBV-associated lymphomas developing after allogeneic marrow transplants.
    O'Reilly RJ, Lacerda JF, Lucas KG, Rosenfield NS, Small TN, Papadopoulos EB.
    Important Adv Oncol; 1996 May 01; ():149-66. PubMed ID: 8791134
    [No Abstract] [Full Text] [Related]

  • 13. The role of virus-specific CD4+ T cells in the control of Epstein-Barr virus infection.
    Mautner J, Bornkamm GW.
    Eur J Cell Biol; 2012 Jan 01; 91(1):31-5. PubMed ID: 21458882
    [Abstract] [Full Text] [Related]

  • 14. Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease.
    Vickers MA, Wilkie GM, Robinson N, Rivera N, Haque T, Crawford DH, Barry J, Fraser N, Turner DM, Robertson V, Dyer P, Flanagan P, Newlands HR, Campbell J, Turner ML.
    Br J Haematol; 2014 Nov 01; 167(3):402-10. PubMed ID: 25066775
    [Abstract] [Full Text] [Related]

  • 15. Immune-cell treatment of Epstein--Barr-virus-associated lymphoproliferative disorders.
    Swinnen LJ.
    Best Pract Res Clin Haematol; 2006 Nov 01; 19(4):839-47. PubMed ID: 16997187
    [Abstract] [Full Text] [Related]

  • 16. B lymphocytes and Epstein-Barr virus: the lesson of post-transplant lymphoproliferative disorders.
    Dolcetti R.
    Autoimmun Rev; 2007 Dec 01; 7(2):96-101. PubMed ID: 18035317
    [Abstract] [Full Text] [Related]

  • 17. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
    Schubert S, Renner C, Hammer M, Abdul-Khaliq H, Lehmkuhl HB, Berger F, Hetzer R, Reinke P.
    J Heart Lung Transplant; 2008 Jan 01; 27(1):100-5. PubMed ID: 18187094
    [Abstract] [Full Text] [Related]

  • 18. Infusions of Epstein-Barr virus-specific cytotoxic T lymphocytes as post-remission therapy in high-risk post-transplant lymphoproliferative disorder patients: report of two cases.
    Kim N, Sohn HJ, Oh JH, Jeon YW, Lee HJ, Cho HI, Chung BH, Yang CW, Kim TG, Cho SG.
    Int J Hematol; 2018 May 01; 107(5):596-603. PubMed ID: 29188583
    [Abstract] [Full Text] [Related]

  • 19. Combination of Epstein-Barr virus nuclear antigen 1, 3 and lytic antigen BZLF1 peptide pools allows fast and efficient stimulation of Epstein-Barr virus-specific T cells for adoptive immunotherapy.
    Wang Y, Aïssi-Rothe L, Virion JM, De Carvalho Bittencourt M, Ulas N, Audonnet S, Salmon A, Clement L, Venard V, Jeulin H, Stoltz JF, Decot V, Bensoussan D.
    Cytotherapy; 2014 Jan 01; 16(1):122-34. PubMed ID: 24094498
    [Abstract] [Full Text] [Related]

  • 20. Post-transplant lymphoproliferative disease in pediatric solid organ transplant recipients.
    Wistinghausen B, Gross TG, Bollard C.
    Pediatr Hematol Oncol; 2013 Sep 01; 30(6):520-31. PubMed ID: 23802715
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.